Tigatuzumab,Abbexa,abx831123
Tigatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF10B/CD262, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tigatuzumab is under investigation in clinical trial NCT00991796, CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC).
Host
Human
Reactivity
Human
Application
ELISA, WB
Conjugate
Unconjugated
Platform ID
BAB049358580
Abbexa
Contact
Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951
Email:
Product Specifications
Specifications
NameTigatuzumab
Cat. No.abx831123
HostHuman
IsotypeIgG1-ND
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
ConcentrationBatch-dependent, typically between 0.5-2.0 mg/ml.
TargetTNFRSF10B/CD262
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.